Exelixis Reports Strong FY2025 Financials, Advances Zanzalintinib NDA, and Secures Key CABOMETYX Patent Protection

summarizeSummary

Exelixis reported strong FY2025 financial results with significant revenue and EPS growth, driven by CABOMETYX sales. The company achieved a major regulatory milestone with the FDA acceptance of its zanzalintinib NDA for metastatic colorectal cancer and secured key patent protection for CABOMETYX against generic challenges, extending exclusivity.

check_boxKey Events

• Strong Financial Performance

  Reported net product revenues of $2.12 billion (+17% YoY) and diluted EPS of $2.78 (+58% YoY) for fiscal year 2025, demonstrating robust commercial execution.

• Zanzalintinib NDA Accepted by FDA

  The FDA accepted the New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, assigning a standard review with a PDUFA target action date of December 3, 2026.

• Key Patent Protection for CABOMETYX Secured

  A Delaware District Court ruling rejected MSN's invalidity challenge to several CABOMETYX patents, preventing generic entry before January 15, 2030. Additionally, Exelixis reached a settlement agreement with Sun Pharmaceutical Industries, terminating ongoing Hatch-Waxman litigation.

• Substantial Share Repurchase Program

  The company authorized and executed significant share repurchases, completing $1.16 billion by year-end 2025 and retaining $590.2 million available under the October 2025 authorization.

auto_awesomeAnalysis

Exelixis's 2025 annual report highlights a period of robust financial growth and significant strategic advancements. The company delivered strong revenue and earnings per share increases, demonstrating solid commercial execution for its flagship product, CABOMETYX. A pivotal development is the FDA's acceptance of the New Drug Application for zanzalintinib in metastatic colorectal cancer, marking a critical step towards potentially launching a new oncology franchise. This is further bolstered by favorable outcomes in patent litigation for CABOMETYX, which significantly extends market exclusivity and de-risks a substantial portion of the company's revenue stream from generic competition. The company's aggressive share repurchase program underscores management's confidence and commitment to returning capital to shareholders. While some pipeline programs were discontinued, this is a common and necessary part of drug development, allowing resources to be reallocated to more promising candidates, as evidenced by the advancement of several novel small molecules and biotherapeutics. Investors should view this report as highly positive, reinforcing the company's strong market position and future growth potential.